Clinical Trial: The CARDIOPROTECT Trial

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07654426) titled 'The CARDIOPROTECT Trial' on June 12.

Brief Summary: This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments.

The names of the study drugs involved in this study are:

* Dexrazoxane (a type of Topoisomerase II Inhibitor)

* Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor)

* Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)

* Standard of care pola-R-CHP t...